ALLERGAN, INC. v. Sandoz, Inc.
818 F. Supp. 2d 974
E.D. Tex.2011Background
- Consolidation of four Hatch-Waxman patent-infringement suits by Allergan against Sandoz, Alcon, Apotex, and Watson seeking to market generic Combigan®.
- Patents-in-suit cover fixed combinations of 0.2% brimonidine and 0.5% timolol for glaucoma/ocular hypertension with claims to methods, compositions, and packaging.
- Defendants filed ANDAs and Paragraph IV certifications; Allergan asserted infringement under 35 U.S.C. § 271(e)(2) and validity of the patents.
- Court conducted a four-day bench trial (August 2–5, 2011) and held the asserted claims infringed and not invalid.
- The court construed and analyzed anticipation (DeSantis) and obviousness (KSR framework) and discussed formulation challenges and secondary considerations.
- The court declined to reach invalidity under 35 U.S.C. § 112 for claims 1–3 of the '149 patent as those issues were mooted/estopped by stipulations and prior rulings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Infringement of asserted claims by ANDA products. | Allergan contends Defendants’ ANDAs meet all claim limitations. | Defendants argue non-infringement or non-applicability of claims. | Infringement established; defendants’ products meet all asserted claim limitations. |
| Validity of the patents over prior art DeSantis (anticipation/obviousness). | DeSantis does not anticipate or render obvious the claims. | DeSantis anticipates/renders obvious the fixed-combination claims. | Court rejects anticipation and obviousness; patents not invalid. |
| Whether the asserted claims are invalid under 35 U.S.C. § 112 (written description/enablement). | Claims satisfy written description and enablement. | Claims fail §112 requirements. | Court declines to reach §112 validity; issues mooted/judicially estopped. |
| Role of secondary considerations and FDA approval in the obviousness analysis. | Secondary considerations support non-obviousness. | Do not render non-obviousness; routine optimization suggested by art. | Secondary considerations support non-obviousness; overall non-obvious. |
Key Cases Cited
- Xerox Corp. v. 3Com Corp., 458 F.3d 1310 (Fed. Cir. 2006) (anticipation requires identical disclosure of all elements in a single reference)
- Graham v. John Deere Co., 383 U.S. 1 (U.S. 1966) (framework for evaluating obviousness (fact-finding with objective indicia))
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. 2007) (teaches a flexible, common-sense approach to obviousness)
- Glaxo, Inc. v. Novopharm Ltd., 52 F.3d 1043 (Fed. Cir. 1995) (prior art must enable the skilled person to practice the invention)
- In re Omeprazole Patent Litigation, 483 F.3d 1364 (Fed. Cir. 2007) (anticipation and enablement considerations in chemical arts)
- Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc., 520 F.3d 1358 (Fed. Cir. 2008) (secondary considerations as independent evidence of non-obviousness)
- Eisai Co. Ltd. v. Dr. Reddy's Labs., Ltd., 533 F.3d 1353 (Fed. Cir. 2008) (unpredictability of art affects obviousness analysis)
- Teleflex, Inc. v. Ficosa North America Corp., 299 F.3d 1313 (Fed. Cir. 2002) (antennal standard for anticipation and combining references)